GVAX

February 5, 2012

Past Pitfalls and Potential Promise for Pancreatic Cancer

October 25, 2010 By MD Becker Partners Leave a Comment

pancreatic_slide

Next month [November] marks Pancreatic Cancer Awareness Month. Visibility for the disease is already on the rise due to recent celebrity victims, including Apple’s Steve Jobs and Hollywood actor Patrick Swayze. According to the American Cancer Society, pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year survival rate lower [...]

Filed Under: Articles Tagged With: 90Y-hPAM4, AAPL, Abraxane, Abraxis BioScience, Afinitor, ALPMY.PK, AMG 479, Amgen, AMGN, Aphton Corp, Apple, ASG-5ME, Astellas Pharma, Bayer Schering Pharma AG, BioSante Pharmaceuticals, BPAX, CA19-9, CDX-1307, CELG, Celgene Corporation, Celldex Therapeutics, CLDX, Clivatuzumab tetraxetan, Eli Lilly, ensituximab, everolimus, gemcitabine, Gemzar, GenVec, GI-4000, GlobeImmune, GNVC, GVAX, ImClone Systems, IMMU, Immunomedics, INFI, Infinity Pharma, IPI-926, LLY, Neogenix Oncology, Neuroendocrine tumors, Novartis, NPC-1C, NVS, Oncolytics Biotech, ONCY, paclitaxel, pancreatic cancer, Patrick Swayze, PCI-27483, PCYC, PFE, Pfizer, Pharmacyclics, PTK787, Regeneron Pharmaceuticals, REGN, Roche Holdings, Sanofi-Aventis, SciClone Pharmaceuticals, SCLN, Seattle Genetics, SGEN, SNY, Steve Jobs, SuperGen, SUPG, TH-302, Therion Biologics, THLD, Threshold Pharmaceuticals, Vatalanib, ZK-222584)

Cancer Vaccine Therapies: Failures and Future Opportunities

April 7, 2010 By MD Becker Partners 3 Comments

FIGURE 1: FDA APPROVAL OF CANCER MABS FROM 1997-2010

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]

Filed Under: Articles Tagged With: active immunotherapy, AGEN, allogeneic, Allovectin-7, American Society for Clinical Oncology, Antigenics, Arzerra, ASCO, autologous, Bavarian Nordic, BIIB, Biogen Idec, Biologics License Application, biotechnology, BiovaxID, Biovest International, BMY, Bristol-Myers Squibb Company, BVTI, cancer vaccine, CD20, CDX-110, Celldex Therapeutics, CTLA-4, Dendreon, dendritic cells, DNDN, EGFRvIII, Genmab A/S, GlaxoSmithKline, GM-CSF, gp100, GSK, GVAX, immunotherapy, ipilimumab, life sciences, lung cancer, MAGE-3, MAGE-A3 ASCI, MD Becker Partners, melanoma, monoclonal antibodies, NCI, NHL, non-Hodgkin’s Lymphoma, NSCLC, ofatumumab, Oncophage, passive immunotherapy, PDUFA, PFE, Pfizer, prostate cancer, prostatic acid phosphatase, PROSTVAC, Provenge, RHHBY, Rituxan, rituximab, Roche Group, sipuleucel-T, TRICOM, vaccine, Vical, VICL